---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-152493"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:20.017914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study

## Summary
- 92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.
- One Cohort 2 patient alive and progression-free at 34.9+ months; IDH-mutant glioma case.
- No CRS, ICANS, or dose-limiting toxicities; common AEs were Grade 1-2 related to TMZ.
- Phase 2 INB-400 now dosing newly diagnosed GBM patients with up to six infusions.
- Radiographic improvements included resolution of midline shift and 36% lesion decrease in one patient.

## SEC filing metadata
- accession: 0001193125-24-152493
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/0001193125-24-152493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524152493/d777605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-152493
- JSON: https://secwatch.observer/filing/0001193125-24-152493.json
- Plain text: https://secwatch.observer/filing/0001193125-24-152493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.